🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Nausea and Vomiting

    phase 3 small molecule active

    1 trial

  2. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Atopic Dermatitis

    phase 3 small molecule completed

    3 trials

  3. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Idiopathic Gastroparesis

    phase 3 small molecule active

    2 trials

  4. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Coronavirus Infection

    phase 3 small molecule active

    1 trial

  5. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Motion Sickness

    phase 3 small molecule active

    4 trials

  6. Tranexamic Acid

    Arrowhead Pharmaceuticals Ireland Limited

    Hemorrhagic Shock

    phase 3 small molecule completed

    1 trial

  7. Transcranial Magnetic stimulation

    CNS Pharmaceuticals

    Gambling Disorder

    phase 3 other active

    1 trial

  8. Trifarotene 0.005 % Topical Cream

    Teva Pharma GmbH

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  9. Trofinetide

    Acadia Pharmaceuticals B.V.

    Rett Syndrome

    phase 3 small molecule completed

    4 trials

  10. Troriluzole, Placebo for BHV-4157 capsules, 100mg, 140mg, Troriluzole

    Lacuna Pharma Pty Ltd

    Obsessive Compulsive Disorder

    phase 3 small molecule active

    1 trial

  11. Troriluzole, Troriluzole

    Lacuna Pharma Pty Ltd

    Obsessive Compulsive Disorder

    phase 3 small molecule active

    1 trial

  12. UGN-102 (Mitomycin)

    Lacuna Pharma Pty Ltd

    Non-Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  13. UGN-103 (Mitomycin)

    Lacuna Pharma Pty Ltd

    Nonmuscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  14. UGN-104

    Lacuna Pharma Pty Ltd

    Low-grade Upper Tract Urothelial Cancer

    phase 3 small molecule active

    1 trial

  15. VALACICLOVIR ARROW 500 mg, comprimé pelliculé sécable, PREVYMIS PLACEBO, VALACICLOVIR PLACEBO, PREVYMIS 240 mg film-coated tablets

    Pari Pharma GmbH

    Diseases [C] - Virus Diseases [C02]

    phase 3 small molecule active

    1 trial

  16. VAY736

    Novartis Pharmaceuticals

    Sjogren Syndrome

    phase 3 mab active

    1 trial

  17. VAY736, -, Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe

    Novartis Pharmaceuticals

    Sjögren’s Syndrome

    phase 3 small molecule active

    1 trial

  18. VAY736, ENTECAVIR , Placebo to VAY736, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  19. VEC-162 20 mg

    Vanda Pharmaceuticals Netherlands B.V.

    Primary Insomnia

    phase 3 small molecule completed

    1 trial

  20. VELCADE 3.5 mg powder for solution for injection, Cyclophosphamide Tablets 50 mg, JNJ-54767414, Dexamethason 4 mg JENAPHARM®

    Janssen-Cilag International N.V.

    AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)

    phase 3 small molecule active

    1 trial

  21. VENETOCLAX, VENETOCLAX, BENDAMUSTINE, ACALABRUTINIB, CYCLOPHOSPHAMIDE, OBINUTUZUMAB, VENETOCLAX, FLUDARABINE, RITUXIMAB

    Lacuna Pharma Pty Ltd

    Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

    phase 3 small molecule active

    1 trial

  22. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Cervical Dysplasia

    phase 3 mab completed

    2 trials

  23. VISIPAQUE 320 mg d’I/mL, solution injectable, LIPIODOL ULTRA FLUIDE 480 mg/ml, solution injectable, HEPARINE CHOAY 5 000 UI/1 ml, solution injectable, XYLOCAINE 5 mg/ml SANS CONSERVATEUR, solution injectable, Optiray 300 (300 mg I/mL), solution injectable en flacon

    Pari Pharma GmbH

    Knee OsteoArthritis

    phase 3 small molecule active

    1 trial

  24. VNZ/TEZ/D-IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    4 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources